Cardiovascular Breakthrough: Novel Minimally Invasive Device A-FLUX Reducer Enters U.S. Clinical Trials for Coronary Microvascular Dysfunction

Jun 27, 2026 07:00 CST Updated 07:00

VahatiCor

Medical Device Developer

In the field of diagnosis and treatment of cardiovascular diseases, mature diagnostic and therapeutic systems have long been established for conditions such as aortic stenosis and myocardial infarction. However, a cardiac issue that is easily overlooked by the general public and even clinicians has long plagued a vast number of patients, yet lacks targeted treatment options—this is Coronary Microvascular Dysfunction (CMD).

A Milestone Breakthrough in Global Minimally Invasive Cardiovascular Care! The United States Has Officially Launched the SERRA-I Early Feasibility Clinical Study of the A-FLUX Reducer System, with the First Patient Enrolled. This Innovative Diagnostic and Therapeutic Device, Specifically Developed for Cardiac Microvascular Disease, Has Officially Commenced Clinical Exploration in the U.S., Bringing New Hope to Millions of Patients Suffering from Refractory Cardiac Symptoms.

This landmark clinical advancement has completely shattered the therapeutic dilemma of coronary microvascular disease, characterized by the absence of dedicated medications and targeted devices, and holds the promise of fundamentally reshaping the first-line diagnosis and treatment landscape for cardiovascular diseases.

The Severely Neglected "Invisible Killer" of the Heart

Many people assume that chest tightness, chest pain, and cardiac discomfort are invariably caused by blockages in the major coronary vessels. However, clinical practice reveals a significant number of atypical patients who suffer from recurrent angina, chest tightness, shortness of breath, palpitations, and fatigue upon minimal exertion over many years, yet repeated coronary angiography and cardiac CT scans fail to detect any stenosis in the major epicardial arteries.

Such patients are highly likely to have developed coronary microvascular dysfunction (CMD).

Our cardiac blood supply system comprises not only the macroscopic coronary arteries visible to the naked eye but also a dense network of microvasculature distributed throughout the myocardium. These microscopic vessels serve as the primary channels for oxygen delivery and nutrient transport to cardiomyocytes. Any structural abnormalities or functional decline in this microvascular network can directly result in myocardial ischemia, leading to persistent and refractory cardiac symptoms.

Compared to the highly prevalent macrovascular cardiovascular diseases, CMD can be described as a highly insidious “invisible killer of the heart.” This condition is characterized by high incidence rates and significant patient suffering, yet there remains a substantial gap in clinical treatment: currently, neither in the United States nor globally, are there any approved therapies specifically targeting microvascular pathology. Traditional medications and conventional interventional procedures fail to precisely address microvascular issues, leaving a large number of patients with “symptoms that cannot be effectively treated and no available therapeutic options.” These patients endure prolonged suffering, experience a marked decline in quality of life, and face a significantly elevated risk of long-term cardiovascular events.

It is precisely because of the extremely urgent unmet clinical need that the clinical implementation of this innovative minimally invasive device has been regarded as a disruptive breakthrough by the global cardiovascular community.

Major Clinical Milestone Achieved! Novel Minimally Invasive Device Launches U.S. Trial

The A-FLUX reducer system, developed by VahatiCor, Inc., has achieved a key milestone, with the SERRA-I early feasibility study officially enrolling its first U.S. patient, marking the formal commencement of clinical exploration for this innovative device in the United States.

It is reported that the SERRA-I clinical program has previously conducted steady patient enrollment and early-phase human trials in Europe, accumulating sufficient and reliable early clinical data and application experience. The successful enrollment of the first patient in the United States marks a critical step in the global clinical deployment of this technology. Currently, trial centers for this study span multiple countries and regions across the United States and Europe, continuously building a comprehensive global clinical data system to lay a solid foundation for the technology’s implementation.

The enrollment, treatment, and full-course follow-up study of the first U.S. subject in this trial was led by the prestigious Yale-New Haven Hospital. Professor Samit Shah from the hospital serves as a Co-Principal Investigator of the SERRA-I study, providing authoritative assurance of the scientific rigor, strictness, and professionalism of the entire clinical trial.

Harry D. Rowland, CEO of VahatiCor, Inc., stated, “The successful enrollment of the first patient in the United States marks the official entry of the A-FLUX reducer system into U.S. clinical research. Current concepts in cardiovascular diagnosis and treatment are undergoing a profound transformation; microvascular disease is no longer considered a secondary manifestation of large-vessel disease but has emerged as a core cardiac condition requiring first-line targeted intervention. The A-FLUX reducer system was developed specifically to align with this industry shift and address unmet clinical needs. We extend our sincere gratitude to all investigators and participants for enabling the smooth progress of this cutting-edge study.”

Cutting-Edge Minimally Invasive Design: Precisely Addressing Microvascular Challenges

Unlike traditional cardiovascular devices that target only large-vessel disease, the A-FLUX reducer system is one of the few minimally invasive interventional devices worldwide specifically developed for coronary microvascular disease. From its design principles to clinical application, it precisely aligns with the therapeutic needs of CMD, demonstrating strong innovation.

This device is constructed from self-expanding medical-grade nitinol, offering excellent flexibility that conforms perfectly to the physiological characteristics of human blood vessels. It is precisely delivered to the coronary sinus via a minimally invasive catheter-based approach, eliminating the need for thoracotomy or major surgery. With minimal trauma and rapid postoperative recovery, it fully aligns with current trends in cardiovascular care toward minimally invasive, low-risk, and high-safety diagnostic and therapeutic procedures.

Its core therapeutic logic is highly advanced: by precisely regulating the hemodynamic status of the coronary sinus, it optimizes overall blood circulation in the myocardial microvasculature, fundamentally improves microvascular perfusion, and repairs damaged microvascular structures. This approach directly targets the underlying pathology of Coronary Microvascular Dysfunction (CMD), thoroughly addressing the key limitation of traditional therapies that only alleviate symptoms without curing the root cause.

Traditional treatment primarily relies on conservative pharmacological management, which can only provide transient relief of patients' uncomfortable symptoms. In contrast, this innovative device directly intervenes at the blood flow level to repair microvascular pathology, achieving targeted, root-cause therapy and effectively filling the long-standing global gap in precise interventional treatment for coronary microvascular disease.

Reshaping the Diagnostic and Treatment Landscape! Millions of Patients Welcome a New Path

Professor Samit Shah, one of the key investigators of this study, precisely articulated its core value: “Patients with coronary microvascular disease suffer from chronic symptoms, yet existing treatment options are extremely limited. Currently, there is no approved diagnostic or therapeutic regimen in the United States that directly targets cardiac microvascular pathology.”

He stated that the successful enrollment of the first U.S. patient marks a critical step in accumulating high-quality clinical evidence, and opens up an entirely new therapeutic pathway for countless CMD patients who have exhausted all other treatment options.

From the perspective of the overall development of the cardiovascular industry, this breakthrough holds milestone significance:

Historically, the global focus in cardiovascular diagnosis and treatment has been almost exclusively on stenosis and occlusion of the major cardiac vessels, long neglecting the hazards of microvascular disease. The clinical implementation of the A-FLUX reducer system marks a new era in cardiovascular care: evolving from “treating only large vessels” to “addressing both large and small vessels with precise targeting of the microvasculature,” thereby addressing a longstanding core gap in the field of cardiovascular diagnosis and treatment.

A Promising Future! New Strength Added to Minimally Invasive Cardiovascular Therapy

Currently, the SERRA-I clinical study in the United States has been fully launched. Patient enrollment will continue to expand in order to accumulate sufficient clinical data and comprehensively validate the safety and clinical efficacy of this device. Upon successful completion of the clinical trials, the A-FLUX reducer system is expected to be rapidly introduced into clinical practice for formal application.

For patients who have suffered from chronic chest tightness and pain for years, with normal test results and a diagnosis of coronary microvascular dysfunction (CMD) but no effective treatment available, this represents not merely a simple breakthrough in medical technology, but a new hope for freeing themselves from suffering and regaining their health.

We eagerly anticipate the subsequent clinical outcomes of this cutting-edge minimally invasive device, hoping for its early global adoption to disrupt traditional CMD treatment paradigms, pioneer a new frontier in the diagnosis and therapy of coronary microvascular disease, and safeguard the cardiac health of more individuals!

# Heart Health # Medical Breakthrough # Minimally Invasive Cardiovascular Therapy #CMD Microvascular Disease # Frontier Medicine